Cost-Effectiveness of a Home Telemonitoring System for Asian Adults with Type 2 Diabetes Mellitus

被引:1
|
作者
Tan, Sharon Hui Xuan [1 ,2 ]
Ang, Seng Bin [3 ,4 ]
Tan, Ngiap Chuan [5 ,6 ]
Lee, Cia Sin [5 ,6 ]
Koh, Eileen Yi Ling [5 ]
Koh, Gerald Choon Huat [1 ,2 ,3 ]
Wang, Yi [1 ,2 ]
机构
[1] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore
[2] Natl Univ Hlth Syst, Singapore, Singapore
[3] MOH Off Healthcare Transformat, Future Primary Care, Singapore, Singapore
[4] KK Womens & Childrens Hosp, Singapore, Singapore
[5] SingHlth Polyclin, Res Dept, Singapore, Singapore
[6] SingHlth Duke NUS Family Med Acad Clin Programme, Singapore, Singapore
关键词
telemedicine; primary health care; diabetes mellitus; blood glucose self-monitoring; glycemic control; TELEMEDICINE; EDUCATION;
D O I
10.1089/tmj.2024.0143
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Telemonitoring programs have been found to be effective in improving diabetic control by promoting patients' self-management of diabetes through medication adherence, dietary modifications, and exercise. Nonetheless, few studies have assessed the cost-effectiveness of telemonitoring for the self-management of diabetes based on real-world data.Methods: A randomized controlled trial entitled Optimizing care of Patients via Telehealth In Monitoring and Augmenting their control of Diabetes Mellitus was conducted among adults with Type 2 Diabetes Mellitus in Singapore. Individuals in the intervention group (n = 159) underwent a telemonitoring program comprising of remote patient monitoring, education, individualized health coaching, and teleconsultations, whereas individuals in the control group (n = 160) received regular care. Economic evaluation was conducted from health care system and societal perspectives in 2020 in Singapore dollars, using health outcomes and costs documented at baseline and at 6 month follow-up. One-way sensitivity analyses and bootstrapping to generate scatter plot on cost-effectiveness planes were done.Results: The adjusted reduction in HbA1c scores was greater in the intervention group by -0.41 (95% confidence interval [CI], -0.65 to -0.17), while the change in utility scores was higher in the intervention group by 0.011 (95% CI, -0.016 to 0.0378). From a health care perspective, the incremental cost-effectiveness ratio (ICER) of the telemonitoring program per unit improvement in HbA1c, per additional case of well-controlled diabetes, and per unit improvement in quality adjusted life years was SGD 580.44, SGD 9100.15, and SGD 21,476.36, respectively. From a societal perspective, the ICERs were SGD 817.20, SGD 12,812.02, and SGD 30,236.36, respectively.Conclusions: The Optimizing care of Patients via Telehealth In Monitoring and Augmenting their control of Diabetes Mellitus telemonitoring program was effective and potentially cost-effective for the management and control of diabetes among patients in primary care.
引用
收藏
页码:2353 / 2362
页数:10
相关论文
共 50 条
  • [21] The cost-effectiveness of screening for type 2 diabetes
    Engelgau, MM
    Narayan, KMV
    Thompson, TJ
    Boyle, JP
    Williamson, DF
    Manninen, DL
    Dong, FB
    Orians, CE
    Dasbach, EJ
    Teutsch, SM
    Eastman, R
    Herman, WH
    Songer, TJ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (20): : 1757 - 1763
  • [22] COST-EFFECTIVENESS OF INDIVIDUALIZING GLYCEMIC GOALS FOR US ADULTS WITH TYPE 2 DIABETES
    Laiteerapong, Neda
    Cooper, Jennifer
    Naylor, Rochelle N.
    Huang, Elbert S.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2016, 31 : S169 - S170
  • [23] Pharmacologic Treatments in Adults With Type 2 Diabetes: Cost-Effectiveness and Comorbidity Considerations
    Syed, Fatima Z.
    ANNALS OF INTERNAL MEDICINE, 2024, 177 (05) : 680 - 681
  • [24] COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN IN THE TREATMENT OF TYPE-2 DIABETES MELLITUS IN SPAIN
    Capel, M.
    Pomares, E.
    Perez-Alcantara, F.
    Simon, S.
    VALUE IN HEALTH, 2020, 23 : S508 - S508
  • [25] Cost-effectiveness of Rosiglitazone Combination Therapy for the Treatment of Type 2 Diabetes Mellitus in the UK
    Sophie Beale
    Adrian Bagust
    Arran T. Shearer
    Alan Martin
    Lisa Hulme
    PharmacoEconomics, 2006, 24 (Suppl 1) : 21 - 34
  • [26] Cost-effectiveness analysis of a pharmacotherapeutic empowerment strategy for patients with type 2 diabetes mellitus
    Oliveira Goncalves, Ana Carolina
    Cazarim, Maurilio de Souza
    Sanches, Cristina
    Leira Pereira, Leonardo Regis
    Tome Camargos, Ana Marcia
    Aquino, Jessica Azevedo
    Baldoni, Andre Oliveira
    BMJ OPEN DIABETES RESEARCH & CARE, 2019, 7 (01)
  • [27] The cost-effectiveness of pioglitazone in combination with metformin in the treatment of type 2 diabetes mellitus in Scotland
    Stynes, G
    Tilden, D
    Swift, M
    Cockle, S
    Haycox, A
    Aristides, M
    VALUE IN HEALTH, 2004, 7 (06) : 737 - 738
  • [28] THE COST-EFFECTIVENESS OF DULAGLUTIDE VERSUS LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TAIWAN
    Lin, H.
    Babineaux, S.
    Lew, T.
    Lowin, J.
    Lovato, E.
    Strizek, A. A.
    Rajan, N.
    VALUE IN HEALTH, 2016, 19 (07) : A898 - A898
  • [29] Cost-Effectiveness of Dulaglutide Versus Liraglutide for Management of Type 2 Diabetes Mellitus in Iran
    Ekhlasi, Mahna
    Taheri, Saeed
    Yousefi, Nazila
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 32 : 54 - 61
  • [30] Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications
    Araujo De Oliveira, Gustavo Laine
    Guerra Junior, Augusto Afonso
    Godman, Brian
    Acurcio, Francisco de Assis
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2017, 17 (02) : 109 - 119